Rodon, Jordi

Actively personalized vaccination trial for newly diagnosed glioblastoma

Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature

Glioma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 938

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 780

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA -Mutant Breast Cancer

Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 332

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

Elkabets, M., Pazarentzos, E., Juric, D., Sheng, Q., Pelossof, R. A., Brook, S., Benzaken, A. O., Rodon, J., Morse, N., Yan, J. J., et al. (2015) · Cancer Cell

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 325

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 273

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Shapiro, G. I., Rodon, J., Bedell, C., Kwak, E. L., Baselga, J., Braña, I., Pandya, S. S., Scheffold, C., Laird, A. D., Nguyen, L. T., et al. (2014) · Clinical Cancer Research

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 152

A CT-based Radiomics Signature is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Ligero, M., Garcia-Ruiz, A., Viaplana, C., Villacampa, G., Raciti, M. V., Landa, J., Matos, I., Martin-Liberal, J., Ochoa-de-Olza, M., Hierro, C., et al. (2021) · Radiology

Radiomics and Machine Learning in Medical ImagingCancer Immunotherapy and Biomarkers

Cited by 107

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson, M., El-Khoueiry, A., Hafez, N., Lakhani, N., Mamdani, H., Rodon, J., Sanborn, R. E., Garcia-Corbacho, J., Boni, V., Stroh, M., et al. (2021) · Clinical Cancer Research

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 72

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., et al. (2024) · Annals of Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 9